ArticleBlood2007
Erythropoietin modulation of podocalyxin and a proposed erythroblast niche.
Article in Blood, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 53 citations in OpenAlex.
- IL-17 stimulates erythropoiesis in vivo by amplifying the response of erythroid progenitors to erythropoietin.PLoS biology · 2025Article
- Stem Cell Niche Concept: Search for Current Expert Consensus.International journal of molecular sciences · 2025Review
- Hematopoietic effects of Fufang E'jiao Jiang revealed by microbiome, metabolome and transcriptome analyses: a multi-omics strategy.Frontiers in immunology · 2025Article
- Podocalyxin in Normal Tissue and Epithelial Cancer.Cancers · 2021Review
- Podocalyxin is required for maintaining blood-brain barrier function during acute inflammation.Proceedings of the National Academy of Sciences of the United States of America · 2019Article
- Novel roles for podocalyxin in regulating stress myelopoiesis, Rap1a, and neutrophil migration.Experimental hematology · 2017Article
- Targeted shRNA screening identified critical roles of pleckstrin-2 in erythropoiesis.Haematologica · 2014Article
- Expression of podocalyxin separates the hematopoietic and vascular potentials of mouse embryonic stem cell-derived mesoderm.Stem cells (Dayton, Ohio) · 2014Article
- Significant biochemical, biophysical and metabolic diversity in circulating human cord blood reticulocytes.PloS one · 2013Article
- miR-199b-5p directly targets PODXL and DDR1 and decreased levels of miR-199b-5p correlate with elevated expressions of PODXL and DDR1 in acute myeloid leukemia.American journal of hematology · 2012Article
- Osteoclasts and hematopoiesis.BoneKEy reports · 2012Article
- Article
- Erythropoiesis, anemia and the bone marrow microenvironment.International journal of hematology · 2011Review
- Article
- Genome-wide identification of TAL1's functional targets: insights into its mechanisms of action in primary erythroid cells.Genome research · 2010Article
- Erythropoietin receptor response circuits.Current opinion in hematology · 2010Review
- Gene profiling of the erythro- and megakaryoblastic leukaemias induced by the Graffi murine retrovirus.BMC medical genomics · 2010Article
- Article
- A KIT juxtamembrane PY567 -directed pathway provides nonredundant signals for erythroid progenitor cell development and stress erythropoiesis.Experimental hematology · 2009Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
Epo's erythropoietic capacity is ascribed largely to its antiapoptotic actions. In part via gene profiling of bone marrow erythroblasts, Epo is now shown to selectively down-modulate the adhesion/migration factors chemokine receptor-4 (Cxcr4) and integrin alpha-4 (Itga4) and to up-modulate growth differentiation factor-3 (Gdf3), oncostatin-M (OncoM), and podocalyxin like-1 (PODXL). For PODXL, Epo dose-dependent expression of this CD34-related sialomucin was discovered in Kit(+)CD71(high) proerythroblasts and was sustained at subsequent Kit(-)CD71(high) and Ter119(+) stages. In vivo, Epo markedly induced PODXL expression in these progenitors and in marrow-resident reticulocytes. This was further associated with a rapid release of PODXL(+) reticulocytes to blood. As studied in erythroblasts expressing minimal Epo receptor (EpoR) alleles, efficient PODXL induction proved dependence on an EpoR-PY343 Stat5 binding site. Moreover, in mice expressing an EpoR-HM F343 allele, compromised Epo-induced PODXL expression correlated with abnormal anucleated red cell representation in marrow. By modulating this select set of cell-surface adhesion molecules and chemokines, Epo is proposed to mobilize erythroblasts from a hypothesized stromal niche and possibly promote reticulocyte egress to blood.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.